No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ARCT Arcturus Therapeutics
- 26.490
- +0.320+1.22%
Trading Apr 26 10:38 ET
712.98MMarket Cap-23651P/E (TTM)
26.800High25.840Low34.75KVolume26.280Open26.170Pre Close915.93KTurnover0.14%Turnover RatioLossP/E (Static)26.92MShares43.81052wk High2.56P/B650.33MFloat Cap17.52052wk Low--Dividend TTM24.55MShs Float129.710Historical High--Div YieldTTM3.67%Amplitude4.110Historical Low26.354Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
We're Interested To See How Arcturus Therapeutics Holdings (NASDAQ:ARCT) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring
As More Rare Disease Therapies Launch, Their Prices Are Rising
Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares
Arcturus Therapeutics(ARCT.US) Officer Sells US$610.57K in Common Stock
$Arcturus Therapeutics(ARCT.US)$ Officer Chivukula Pad sold 17,435 shares of Common Stock on Mar 25, 2024 at an average price of $35.02 for a total value of $610.57K.Source: Announcement What is state
Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing
Pad Chivukula, Chief Scientific Officer & COO, on March 25, 2024, sold 17,435 shares in Arcturus Therapeutics Holdings (ARCT) for $610,574. Following the Form 4 filing with the SEC, Chivukula has cont
Comments
Analysts maintain loss per share estimates for next year with no major changes to revenue estimates. However, the company's performance is expected to underperform the wider industry. The steady consensus price target indicates that reduced loss estimates may not positively impact the stock's long-term valuation.
Analysts Have Made A Financial Statement On Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Yearly ReportDespite Arcturus Therapeutics Holdings Inc.'s strong run, its P/S ratio remains low due to a weak revenue outlook. Investors believe the potential for revenue improvement doesn't justify a higher P/S ratio, forming a barrier for the share price.
The recent improvement in total shareholder return could indicate that the business is getting better over time. However, there are 2 warning signs that investors should be aware of. The sentiment around the company seems to be positive lately.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg